• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
    • Special Meeting Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024 | Press Releases

CINCINNATI, Ohio, July 11, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642...

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024 | Press Releases

CINCINNATI, Ohio, July 11, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024 | Press Releases

CINCINNATI, Feb. 13, 2024 — Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024 | Press Releases

CINCINNATI, Feb. 13, 2024 — Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and...

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 19, 2023 | Press Releases

CINCINNATI, Dec. 19, 2023 — Onconetix, Inc., (Nasdaq: BWV) (“Onconetix” or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As...

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Dec 18, 2023 | Press Releases

Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancerCINCINNATI, Dec. 18, 2023 — Blue Water Biotech, Inc. (Nasdaq: BWV) (“BWB” or the “Company”) today announced the...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
  • Onconetix Announces Reverse Stock Split
  • Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
  • CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
  • Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2026 Onconetix